

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

## **Olerup SSP<sup>®</sup> HLA-C low resolution screening**

<b>Product number:</b>	<b>101.603-24/12 – including <i>Taq</i> pol. 101.603-24u/12u – without <i>Taq</i> pol.</b>
<b>Lot number:</b>	<b>81N</b>
<b>Expiry date:</b>	<b>2014-October-01</b>
<b>Number of tests:</b>	<b>24 tests – Product No. 101.603-24/24u 12 tests – Product No. 101.603-12/12u</b>
<b>Number of wells per test:</b>	<b>23 + 1</b>
<b>Storage - pre-aliquoted primers:</b>	<b>dark at -20°C</b>
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

**This Product Description is only valid for Lot No. 81N.**

The Lot-specific Information for HLA-C low resolution screening including and without *Taq* polymerase is described in one common Product Insert.

Change in revision R01 compared to R00:

1. Correction of the product number in the Declaration of Conformity.

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

**Lot-specific information**

Well **24** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup* SSP<sup>®</sup> HLA Class I, DRB, DQB1 and DPB1 amplicons as well as amplicons generated by a control primer pair.

PCR product sizes range from 75 to 430 base pairs.

The PCR product generated by the control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>DRB1</b>				<b>+</b>	<b>+</b>	
<b>DRB3</b>				<b>+</b>	<b>+</b>	
<b>DRB5</b>				<b>+</b>		
<b>DQB1</b>					<b>+</b>	
<b>DPB1</b>						<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-C-low resolution screening SSP subtyping

#### CONTENT

The primer set contains 5'- and 3'-primers for grouping the HLA-C\*01:02 to C\*18:05 alleles into the groups C\*01:xx to C\*18:xx.

#### PLATE LAYOUT

Each test consists of 24 PCR reactions in a 24 well cut PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24

Wells 1 to 31 – HLA-C low resolution screening primers.

Well 24 – Negative Control.

The 24 well cut PCR plate is marked with ‘HLA-C low screening’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘64N’.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

**Please note:** When removing each 24 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Only HLA-C alleles will be amplified by the HLA-C low resolution screening typing kit, except that primer mix 1 will amplify the B\*54:18 allele, primer mix 13 will amplify the B\*67:02 allele, primer mix 20 will amplify the B\*14:03 allele and primer mix 23 will amplify the A\*24:106, A\*24:174 and B\*46:25 alleles. Thus, the interpretation of HLA-C low resolution screening typings is only influenced by these six alleles and not by other HLA class I genes.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-C alleles, i.e. **C\*01:02 to C\*18:05**, recognized by the HLA Nomenclature Committee in January 2012<sup>1</sup> will be amplified by the primers in the HLA-C low resolution screening SSP kit<sup>2</sup>. The HLA-C alleles will be grouped into the C\*01:xx to C\*18:xx groups.

<sup>1</sup>HLA-C alleles listed on the IMGT/HLA web page 2012-January-12, release 3.7.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>The C\*01:05, 01:22 and 01:35-01:36 and the B\*54:18 alleles give rise to identical amplification patterns with the HLA-C low resolution screening primer set. These alleles are separated by the HLA-B low primer set.

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

## SPECIFICITY TABLE

### HLA-C low resolution screening SSP typing

Specificities and sizes of the PCR products of the 23+1 primer mixes used for HLA-C low resolution SSP typing

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA class I alleles <sup>3,4</sup>
<b>1</b>	155 bp	<b>800 bp</b>	*01:02:01-01:61, <b>B*54:18</b>
<b>2<sup>5</sup></b>	130 bp, 200 bp, 270 bp, 300 bp	<b>800 bp</b>	*01:10, 01:43, 02:02:01-02:02:03, 02:02:05-02:40, 02:42-02:55, 04:32, 04:77, 06:08, 07:101, 07:148, 07:161, 08:31, 14:25, 15:42, 16:29, 17:01:01:01-17:06, 17:08-17:11, 18:03
<b>3<sup>13</sup></b>	280 bp	<b>800 bp</b>	*02:02:01-02:02:03, 02:02:05-02:03, 02:04 <sup>w</sup> , 02:05-02:13, 02:14 <sup>w</sup> , 02:15-02:25Q, 02:26:02-02:40, 02:42-02:55, 03:02:01-03:02:08, 03:04:01:01-03:10, 03:14-03:17, 03:19, 03:23-03:29, 03:32-03:38:02, 03:40:01-03:42, 03:44-03:48, 03:51, 03:54, 03:57, 03:60, 03:63-03:65, 03:70-03:74, 03:77-03:78, 03:80, 03:82, 03:84, 03:87, 03:89-03:95, 03:98, 03:100-03:101, 03:104-03:111, 03:113-03:115, 03:117-03:118, 03:121N, 03:123, 03:125, 03:128-03:131, 03:134-03:136, 03:138-03:139, 04:03, 04:06, 04:16, 04:80, 04:107, 05:58:01, 06:03, 07:96, 15:02:01-15:09, 15:10:02-15:11, 15:13, 15:15-15:22, 15:24-15:35, 15:37-15:56, 16:34
<b>4<sup>6</sup></b>	170 bp, 275 bp	1070 bp	*03:02:01-03:04:06, 03:04:08-03:15, 03:17-03:40:02, 03:42-03:57, 03:59-03:79, 03:81-03:85, 03:87-03:93, 03:95-03:98, 03:100-03:109, 03:111-03:112, 03:114-03:139
<b>5</b>	280 bp	<b>800 bp</b>	*03:03:01-03:03:18, 03:11:01-03:13, 03:20N-03:22Q, 03:30-03:31, 03:43:01-03:43:02, 03:49-03:50, 03:52-03:53, 03:55-03:56, 03:58-03:59, 03:61-03:62, 03:66, 03:67 <sup>w</sup> , 03:68-03:69, 03:75-03:76, 03:79, 03:81, 03:83, 03:85-03:86, 03:88, 03:96-03:97, 03:102-03:103, 03:112, 03:116, 03:119-03:120, 03:122, 03:124, 03:126-03:127, 03:132-03:133, 15:12
<b>6<sup>13</sup></b>	130 bp, 336 bp	<b>800 bp</b>	*02:02:01-02:02:03, 02:02:05-02:02:12, 02:02:14-02:20, 02:22-02:25Q, 02:27:01-02:38N, 02:40, 02:42-02:44, 02:46-02:55, 04:01:01:01-04:01:27, 04:01:29-04:01:36, 04:03-04:15:03, 04:17-04:20, 04:23-04:41, 04:43-04:102, 04:104-04:107, 05:26, 07:02:09, 07:125, 15:11, 15:36, 16:34
<b>7</b>	390 bp, 445 bp	1070 bp	*05:01:01:01-05:01:18, 05:03-05:72, 08:10, 16:40
<b>8</b>	130 bp, 355 bp	<b>800 bp</b>	*02:06, 02:47, 06:02:01:01-06:02:01:02, 06:02:03-06:16N, 06:18-06:31, 06:33-06:69, 12:03:09, 12:15, 15:02:01-15:03,

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

## Lot-specific information

			15:07-15:08, 15:10:01-15:13, 15:15-15:18, 15:21, 15:26, 15:28, 15:31-15:35, 15:37-15:39, 15:41-15:45, 15:47-15:53, 15:56
<b>9<sup>7</sup></b>	245 bp, 425 bp	<b>800 bp</b>	*07:01:01-07:33N, 07:35-07:220
<b>10<sup>8,10,13</sup></b>	115 bp, 165 bp, 265 bp, 390 bp	<b>800 bp</b>	*01:43, 07:101, 07:148, 07:161, 08:01:01-08:56
<b>11</b>	340 bp	1070 bp	*01:14, 01:59, 02:02:01-02:02:03, 02:02:05-02:11, 02:13-02:26:03, 02:28-02:40, 02:42-02:55, 03:07, 03:15, 03:45, 03:130, 04:01:01:01-04:01:36, 04:03-04:10, 04:12-04:20, 04:23-04:28, 04:30-04:35, 04:37-04:54, 04:56-04:107, 05:01:01:01-05:01:18, 05:03-05:72, 06:02:01:01-06:02:01:02, 06:02:03-06:02:11, 06:02:13-06:10, 06:12-06:51, 06:53-06:69, 07:07, 07:09, 07:49, 07:76, 07:210, 08:10, 12:04:01-12:05, 12:09, 12:21, 12:33, 12:41, 12:54, 12:60, 14:04, 14:12, 15:02:01-15:06:03, 15:08-15:13, 15:15-15:20, 15:22-15:24, 15:26-15:42, 15:44-15:56, 16:02:01-16:02:09, 16:09, 16:12, 16:19, 16:25, 17:01:01:01-17:11, 18:01-18:05
<b>12<sup>10,11</sup></b>	100 bp, 160 bp, 220 bp	<b>800 bp</b>	*01:04, 01:21, 12:02:01-12:03:01:02, 12:03:03-12:03:07, 12:03:09-12:03:15, 12:03:17-12:03:19, 12:04:02-12:08, 12:10:01-12:13, 12:14:02-12:25, 12:27-12:32, 12:34-12:58, 12:60-12:68, 14:02:08, 16:15:02
<b>13</b>	130 bp, 250 bp	<b>800 bp</b>	*01:21, 02:12, 02:49, 02:55, 04:01:01:01-04:01:36, 04:03-04:09N, 04:12-04:20, 04:23-04:35, 04:37-04:54, 04:56-04:107, 05:42, 05:46, 07:02:09, 07:125, 08:05, 08:21, 08:25, 12:02:01-12:03:03, 12:03:05-12:03:08, 12:03:10-12:03:12, 12:03:13 <sup>w</sup> , 12:03:14-12:03:20, 12:04:02, 12:06-12:08, 12:10:01-12:20, 12:22-12:32, 12:34-12:48, 12:50-12:68, 15:03, 15:16, 15:25, 16:01:01-16:02:09, 16:06-16:28, 16:30N-16:32, 16:34, 16:36-16:39, 16:41, 16:43-16:44, 17:01:04, <b>B*67:02</b>
<b>14<sup>14</sup></b>	160 bp, 220 bp	<b>800 bp</b>	*01:04, 01:09, 02:05, 02:17, 04:42, 06:02:01:01-06:02:01:02, 06:02:03-06:02:15, 06:02:17-06:03, 06:07-06:13, 06:15-06:34, 06:36-06:39, 06:41-06:69, 07:125, 12:03:01:01-12:07, 12:11-12:13, 12:15, 12:19, 12:23, 12:25-12:26, 12:28-12:29, 12:31-12:35, 12:37-12:39N, 12:42Q-12:43, 12:45-12:48, 12:50-12:55, 12:57-12:63, 12:65-12:66, 14:16, 16:04, 16:29, 16:33, 16:42
<b>15<sup>13</sup></b>	130 bp, 255 bp	1070 bp	*02:02:01 <sup>w</sup> , 02:02:02-02:02:03, 02:02:05-02:13, 02:15-02:26:03, 02:28-02:40, 02:42-02:55, 03:07, 03:10, 03:15, 03:29, 03:45, 03:58, 03:86, 03:94, 03:99, 04:03, 04:06, 04:16, 04:37, 04:80, 04:103, 04:107, 05:01:01:01-05:01:18,

101.603.24/12 – including *Taq pol.*, IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq pol.*, IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

			05:03-05:19, 05:21-05:42, 05:44-05:72, 06:03, 08:10, 12:04:01-12:05, 12:09, 12:21, 12:33, 12:41, 12:60, 15:02:01-15:06:03, 15:08-15:13, 15:15-15:22, 15:24, 15:26-15:35, 15:37-15:42, 15:44-15:56, 16:02:01-16:02:09, 16:09, 16:12, 16:18-16:19, 16:25, 16:37, 17:01:01:01-17:11
<b>16<sup>12</sup></b>	255 bp, 445 bp	1070 bp	*04:11, 04:29, 04:36, 04:55, 07:64, 12:55, 14:02:01-14:11, 14:13-14:34, 16:40
<b>17<sup>9,10</sup></b>	110 bp, 325 bp	<b>800 bp</b>	*02:06, 03:81, 05:36, 07:123, 07:173, 12:08, 12:15, 15:02:01-15:13, 15:15-15:24, 15:26-15:56, 16:20
<b>18<sup>12</sup></b>	180 bp, 210 bp, 240 bp	1070 bp	*02:13, 02:18, 02:33, 02:49, 04:01:01:01-04:01:22, 04:01:24-04:01:36, 04:03-04:10, 04:12-04:20, 04:23-04:32, 04:34-04:106, 05:17, 05:25, 05:42, 05:55, 05:68, 06:05, 06:31, 07:02:09, 07:31, 07:177, 08:01:01-08:01:05, 08:03:01-08:03:02, 08:06, 08:08-08:11, 08:14, 08:16, 08:20-08:22, 08:24, 08:26N, 08:28, 08:36N, 08:38, 08:40-08:42, 08:44, 08:46, 08:50, 08:56, 12:14:01-12:14:02, 12:28, 12:58, 14:10, 14:15, 15:12, 15:25, 16:01:01-16:02:09, 16:04, 16:06-16:39, 16:41-16:42, 16:44
<b>19<sup>11,15</sup></b>	225 bp, 250 bp	<b>800 bp</b>	*01:60, 04:58, 05:23, 05:62, 08:07, 08:47, 12:14:01-12:14:02, 14:17, 15:25, 17:01:01:01-17:11
<b>20</b>	215 bp, 425 bp	<b>800 bp</b>	*01:02:01-01:03, 01:06-01:08, 01:10-01:20, 01:23-01:34, 01:37N-01:48, 01:51-01:54, 01:56N-01:61, 03:58, 03:86, 03:94, 03:99, 04:37, 05:16, 06:05-06:06, 06:17, 06:31, 07:07, 07:09, 07:49, 07:76, 07:210, 08:12, 12:09, 12:24, 14:02:01-14:05, 14:07N, 14:10-14:14, 14:17-14:27, 14:29-14:34, 16:04, 16:29, 16:33, 16:42, 18:01-18:05, <b>B*14:03</b>
<b>21</b>	325 bp, 380 bp	1070 bp	*01:03, 01:24, 01:34, 01:49-01:50, 01:55, 02:22, 03:03:01-03:04:25, 03:06-03:12, 03:14, 03:18-03:24, 03:26, 03:28-03:32, 03:34, 03:37-03:59, 03:61-03:70, 03:72-03:83, 03:85, 03:87-03:88, 03:90-03:93, 03:96, 03:98, 03:100-03:107, 03:109, 03:111-03:120, 03:122-03:131, 03:133-03:134, 03:136-03:138, 04:01:01:01-04:01:15, 04:01:17-04:01:36, 04:03-04:20, 04:24-04:53, 04:55-04:71, 04:73-04:107, 05:01:01:01-05:01:18, 05:03, 05:05-05:21, 05:23-05:72, 06:09, 06:14, 06:35, 07:10, 07:28, 07:41, 07:43, 07:184, 07:196, 08:01:01-08:08, 08:10, 08:12-08:47, 08:49-08:56, 12:31, 12:44, 15:02:01-15:13, 15:15-15:21, 15:23-15:36, 15:38-15:54, 15:56, 17:01:01:01-17:11, 18:01-18:05
<b>22<sup>12</sup></b>	135 bp	1070 bp	*03:02:01-03:04:24, 03:05-03:17, 03:19-03:38:02, 03:40:01-03:66, 03:67 <sup>w</sup> , 03:68-03:98, 03:100-03:136, 03:138-03:139, 04:32, 04:77, 06:03, 07:96, 14:25, 15:43, 18:03
<b>23</b>	160 bp, 235 bp	1070 bp	*04:42, 06:02:01:01-06:02:01:02, 06:02:03-06:02:19, 06:04-06:69, 07:01:01-07:02:07, 07:02:09-07:02:28, 07:03-07:25, 07:27:01-07:32N, 07:35-07:38, 07:41-07:63, 07:65-07:91,

101.603.24/12 – including *Taq pol.*, IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq pol.*, IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

<b>24<sup>16</sup></b>	-	-	<b>Negative Control</b>
------------------------	---	---	-------------------------

07:93-07:95, 07:97-07:138, 07:140-07:151, 07:153-07:155,  
 07:157-07:176, 07:178-07:209, 07:211-07:220, 12:16,  
 16:01:01-16:02:09, 16:06-16:28, 16:30N-16:32, 16:34,  
 16:36-16:39, 16:41, 16:43-16:44, 18:01-18:05, **A\*24:106,**  
**A\*24:174, B\*46:25**

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C low resolution SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective lengths of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C low resolution screening typing.

In addition, wells number 2, 3, 5, 6, 8 to 10, 12 to 14, 17, 19 and 20 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to allow kit identification.

In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA-C alleles only partial 1<sup>st</sup> and 4<sup>th</sup> exon and intron nucleotide sequences are available. In these instances it is not known whether some of the primers of the HLA-C low resolution screening SSP sets are completely matched with the target sequences or not. We assume that unknown sequences are conserved within allelic groups.

<sup>4</sup>Due to sharing of sequence motifs primer mix 1 will amplify the B\*54:18 allele, primer mix 13 will amplify the B\*67:02 allele, primer mix 20 will amplify the B\*14:03 allele and primer mix 23 will amplify the A\*24:106, A\*24:174 and B\*46:25 alleles.

<sup>5</sup>Primer mix 2 will for most C\*02 alleles give rise to two specific PCR fragments.

<sup>6</sup>Primer mix 4 will for most C\*03 alleles give rise to two specific PCR fragments.

<sup>7</sup>Primer mix 9 will for most C\*07 alleles give rise to two specific PCR fragments.

<sup>8</sup>Primer mix 10 will for most C\*08 alleles give rise to multiple specific PCR fragments.

<sup>9</sup>Primer mix 17 will for most C\*15 alleles give rise to two specific PCR fragments.

<sup>10</sup>Specific PCR fragments shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR bands.

<sup>11</sup>Primer mixes 12 and 19 may give rise to unspecific amplification.

<sup>12</sup>Primer mixes 16, 18 and 22 have a tendency of giving rise to primer oligomer artifacts.

<sup>13</sup>Primer mixes 3, 6, 10 and 15 yield somewhat less intense specific PCR fragments than the other HLA-C low resolution primer mixes.

<sup>14</sup>Primer mix 14 might faintly amplify most C\*01 and the C\*14 alleles.

<sup>15</sup>Primer mix 19 might generate a false band of about 500 base pairs. This band should be disregarded when interpreting HLA-C low resolution typings.

<sup>16</sup>Primer mix 24 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicon generated by a control primer pair. PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the control primer pair is 430 base pairs.

'w', might be weakly amplified.

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

INTERPRETATION TABLE												
HLA-C low resolution screening SSP typing												
Amplification patterns of the C*01:02 to C*18:05 alleles												
	Well <sup>6</sup>											
	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	155	130	280	170	280	130	390	130	245	115	340	100
PCR product(s)		200		275		335	445	355	425	165		160
		270								265		220
		300								390		
Length of int. pos. control <sup>1</sup>	800	800	800	1070	800	800	1070	800	800	800	1070	800
5'-primer(s) <sup>2</sup>	89	47	105	355	105	47	1 <sup>st</sup> I	28	47	1 <sup>st</sup> I	1 <sup>st</sup> I	361
	5'-gAA <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-TCA <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-TCA <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-AgT <sup>3'</sup>
		89		459		112	527	2 <sup>nd</sup> I	648	176		419
		2 <sup>nd</sup> I		5'-gAT <sup>3'</sup>		5'-CCT <sup>3'</sup>	5'-TgA <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CAC <sup>3'</sup>	5'-gCA <sup>3'</sup>		5'-gTC <sup>3'</sup>
		118				5'-CCA <sup>3'</sup>				527		
		5'-CCA <sup>3'</sup>								5'-TAC <sup>3'</sup>		
		703										
		5'-CTA <sup>3'</sup>										
3'-primer(s) <sup>3</sup>	201	176	343	589	343	201	302	213	302	175	302	474
	5'-CTC <sup>3'</sup>	5'-ACT <sup>3'</sup>	5'-C <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-T <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-ggT <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-ggT <sup>3'</sup>	5'-gCA <sup>3'</sup>
	201	559	343			218	3 <sup>rd</sup> I	420	853	302	304	477
	5'-CTT <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-g <sup>3'</sup>			5'-gCT <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-CAT <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CAA <sup>3'</sup>	5'-gCA <sup>3'</sup>
		861								601		538
		5'-TCg <sup>3'</sup>								5'-CTT <sup>3'</sup>		5'-gCA <sup>3'</sup>
Well No.	1	2	3	4	5	6	7	8	9	10	11	12



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

INTERPRETATION TABLE											
HLA-C low resolution screening SSP typing											
Amplification patterns of the C*01:02 to C*18:05 alleles											
Well <sup>6</sup>											
13	14	15	16	17	18	19	20	21	22	23	24
120	160	130	255	110	180	225	215	325	135	160	Length of spec. PCR product(s)
250	220	255	445	325	210	250	425	380		235	
					240						
<b>800</b>	<b>800</b>	1070	1070	<b>800</b>	1070	<b>800</b>	<b>800</b>	1070	1070	1070	Length of int. pos. control <sup>1</sup>
201	97	98	98	201	201	2 <sup>nd</sup> I	47	355	105	97	5'-primer(s) <sup>2</sup>
5'-CCA 3'	5'-TCg 3'	5'-CTA 3'	5'-CTC 3'	5'-CCA 3'	5'-CCA 3'	5'-CCA 3'	5'-Agg 3'	5'-TCA 3'	5'-gCT 3'	5'-TCg 3'	
218	361	368	527	409	2 <sup>nd</sup> I		361	412	459	97	
5'-ggA 3'	5'-AgT 3'	5'-gTg 3'	5'-TgA 3'	5'-ggC 3'	5'-CCA 3'		5'-AgT 3'	5'-ATA 3'	5'-gAT 3'	5'-TTg 3'	
2 <sup>nd</sup> I					361					418	
5'-CCA 3'					5'-AgT 3'					5'-Agg 3'	
										419	
										5'-gTC 3'	
289	218	312	311	270	341	512	302	3 <sup>rd</sup> I	201	213	3'-primer(s) <sup>3</sup>
5'-AgC 3'	5'-gCT 3'	5'-AgT 3'	5'-ggT 3'	5'-TAg 3'	5'-CgT 3'	5'-CCA 3'	5'-ggT 3'	5'-CTC 3'	5'-CTC 3'	5'-Cgg 3'	
289	538	361	3 <sup>rd</sup> I	3 <sup>rd</sup> I	343	538	527		559	289	
5'-AgC 3'	5'-CCA 3'	5'-CCA 3'	5'-gCA 3'	5'-CTC 3'	5'-T 3'	5'-gTC 3'	5'-CCg 3'		5'-CTC 3'	5'-AgC 3'	
539	538	459			343		538			289	
5'-TCT 3'	5'-gCA 3'	5'-AgA 3'			5'-g 3'		5'-CCg 3'			5'-AgC 3'	
					527					539	
					527					5'-TCT 3'	
					527						
					527						
					530						
					5'-CCA 3'						
13	14	15	16	17	18	19	20	21	22	23	24
											Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
HLA-C allele <sup>4</sup>												
*01:02:01-01:02:14, 01:06-01:08, 01:11-01:13, 01:15-01:20, 01:23, 01:25-01:33, 01:37N-01:42, 01:44-01:48, 01:51-01:54, 01:56N-01:58, 01:61	1											
*01:03, 01:24, 01:34	1											
*01:04	1											12
*01:05, 01:22, 01:35-01:36, <i>B*54:18</i> <sup>5</sup>	1											
*01:09	1											
*01:10	1	2										
*01:14, 01:59	1										11	
*01:21	1											12
*01:43	1	2								10		
*01:49-01:50, 01:55	1											
*01:60	1											
*02:02:01		2	3			6					11	
*02:02:02-02:02:03, 02:02:05-02:02:12, 02:02:14-02:03, 02:07-02:11, 02:15-02:16:02, 02:19-02:20, 02:23-02:25Q, 02:28-02:32, 02:34-02:38N, 02:40, 02:42-02:44, 02:46, 02:48, 02:50-02:54		2	3			6					11	
*02:02:13, 02:21, 02:26:02-02:26:03, 02:39, 02:45		2	3								11	
*02:04		2	w			6					11	
*02:05, 02:17		2	3			6					11	
*02:06		2	3			6		8			11	
*02:12		2	3			6						
*02:13, 02:18, 02:33		2	3			6					11	
*02:14		2	w			6					11	
*02:22		2	3			6					11	
*02:26:01		2									11	
*02:27:01-02:27:02		2	3			6						
*02:47		2	3			6		8			11	
*02:49		2	3			6					11	
*02:55		2	3			6					11	
*03:02:01-03:02:08, 03:05, 03:17, 03:25, 03:27, 03:33, 03:35-03:36, 03:60, 03:71, 03:84, 03:89, 03:95, 03:108, 03:121N, 03:135, 03:139			3	4								
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
							20					*01:02:01-01:02:14, 01:06-01:08, 01:11-01:13, 01:15-01:20, 01:23, 01:25-01:33, 01:37N-01:42, 01:44-01:48, 01:51-01:54, 01:56N-01:58, 01:61
							20	21				*01:03, 01:24, 01:34
	14											*01:04
												*01:05, 01:22, 01:35-01:36, <i>B*54:18</i> <sup>5</sup>
	14											*01:09
							20					*01:10
							20					*01:14, 01:59
13												*01:21
							20					*01:43
								21				*01:49-01:50, 01:55
						19	20					*01:60
		w										*02:02:01
		15										*02:02:02-02:02:03, 02:02:05-02:02:12, 02:02:14-02:03, 02:07-02:11, 02:15-02:16:02, 02:19-02:20, 02:23-02:25Q, 02:28-02:32, 02:34-02:38N, 02:40, 02:42-02:44, 02:46, 02:48, 02:50-02:54
		15										*02:02:13, 02:21, 02:26:02-02:26:03, 02:39, 02:45
		15										*02:04
	14	15										*02:05, 02:17
		15		17								*02:06
13		15										*02:12
		15			18							*02:13, 02:18, 02:33
		15										*02:14
		15						21				*02:22
		15										*02:26:01
		15										*02:27:01-02:27:02
		15										*02:47
13		15			18							*02:49
13		15										*02:55
									22			*03:02:01-03:02:08, 03:05, 03:17, 03:25, 03:27, 03:33, 03:35-03:36, 03:60, 03:71, 03:84, 03:89, 03:95, 03:108, 03:121N, 03:135, 03:139
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
HLA-C allele <sup>4</sup>												
*03:03:01-03:03:18, 03:11:01-03:12, 03:20N-03:22Q, 03:30-03:31, 03:43:01-03:43:02, 03:49-03:50, 03:52-03:53, 03:55-03:56, 03:59, 03:61-03:62, 03:66, 03:68-03:69, 03:75-03:76, 03:79, 03:83, 03:85, 03:88, 03:96, 03:102-03:103, 03:112, 03:116, 03:119-03:120, 03:122, 03:124, 03:126-03:127, 03:133				4	5							
*03:04:01:01-03:04:06, 03:04:08-03:04:24, 03:06, 03:08-03:09, 03:14, 03:19, 03:23-03:24, 03:26, 03:28, 03:32, 03:34, 03:37-03:38:02, 03:40:01-03:40:02, 03:42, 03:44, 03:46-03:48, 03:51, 03:54, 03:57, 03:63-03:65, 03:70, 03:72-03:74, 03:77-03:78, 03:82, 03:87, 03:90-03:93, 03:98, 03:100-03:101, 03:104-03:107, 03:109, 03:111, 03:114-03:115, 03:117-03:118, 03:123, 03:125, 03:128-03:129, 03:131, 03:134, 03:136, 03:138			3	4								
*03:04:07, 03:41, 03:80, 03:113			3									
*03:04:25			3	4								
*03:07, 03:45			3	4							11	
*03:10, 03:29			3	4								
*03:13, 03:97, 03:132				4	5							
*03:15			3	4							11	
*03:16, 03:110			3									
*03:18, 03:39, 03:137				4								
*03:58					5							
*03:67				4	w							
*03:81				4	5							
*03:86					5							
*03:94			3									
*03:99												
*03:130			3	4							11	
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
								21	22			*03:03:01-03:03:18, 03:11:01-03:12, 03:20N-03:22Q, 03:30-03:31, 03:43:01-03:43:02, 03:49-03:50, 03:52-03:53, 03:55-03:56, 03:59, 03:61-03:62, 03:66, 03:68-03:69, 03:75-03:76, 03:79, 03:83, 03:85, 03:88, 03:96, 03:102-03:103, 03:112, 03:116, 03:119-03:120, 03:122, 03:124, 03:126-03:127, 03:133
								21	22			*03:04:01:01-03:04:06, 03:04:08-03:04:24, 03:06, 03:08-03:09, 03:14, 03:19, 03:23-03:24, 03:26, 03:28, 03:32, 03:34, 03:37-03:38:02, 03:40:01-03:40:02, 03:42, 03:44, 03:46-03:48, 03:51, 03:54, 03:57, 03:63-03:65, 03:70, 03:72-03:74, 03:77-03:78, 03:82, 03:87, 03:90-03:93, 03:98, 03:100-03:101, 03:104-03:107, 03:109, 03:111, 03:114-03:115, 03:117-03:118, 03:123, 03:125, 03:128-03:129, 03:131, 03:134, 03:136, 03:138
								21	22			*03:04:07, 03:41, 03:80, 03:113
								21				*03:04:25
		15						21	22			*03:07, 03:45
		15						21	22			*03:10, 03:29
									22			*03:13, 03:97, 03:132
		15							22			*03:15
									22			*03:16, 03:110
								21				*03:18, 03:39, 03:137
		15					20	21	22			*03:58
								21	w			*03:67
				17				21	22			*03:81
		15					20		22			*03:86
		15					20		22			*03:94
		15					20					*03:99
								21	22			*03:130
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
HLA-C allele <sup>4</sup>												
*04:01:01:01-04:01:15, 04:01:17-04:01:22, 04:01:24- 04:01:27, 04:01:29-04:01:36, 04:04:01-04:05, 04:07-04:09N, 04:12-04:15:03, 04:17-04:20, 04:24-04:28, 04:30-04:31, 04:34- 04:35, 04:38-04:41, 04:43- 04:53, 04:56-04:57, 04:59Q- 04:71, 04:73-04:76, 04:78- 04:79, 04:81-04:102, 04:104- 04:106						6					11	
*04:01:16, 04:23, 04:54, 04:72						6					11	
*04:01:23, 04:33						6					11	
*04:01:28											11	
*04:03, 04:06, 04:80			3			6					11	
*04:10						6					11	
*04:11						6						
*04:16			3								11	
*04:29						6						
*04:32, 04:77		2				6					11	
*04:36, 04:55						6						
*04:37						6					11	
*04:42											11	
*04:58						6					11	
*04:103											11	
*04:107			3			6					11	
*05:01:01:01-05:01:18, 05:03, 05:05-05:15, 05:18:01-05:19, 05:21, 05:24, 05:27-05:35, 05:37-05:41, 05:44-05:45, 05:47- 05:54, 05:56-05:57, 05:58:02- 05:61, 05:63-05:67, 05:69-05:72							7				11	
*05:04, 05:22:01-05:22:02							7				11	
*05:16							7				11	
*05:17, 05:25, 05:55, 05:68							7				11	
*05:20, 05:43							7				11	
*05:23, 05:62							7				11	
*05:26						6	7				11	
*05:36							7				11	
*05:42							7				11	
*05:46							7				11	
*05:58:01			3				7				11	
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
13					18			21				*04:01:01:01-04:01:15, 04:01:17-04:01:22, 04:01:24- 04:01:27, 04:01:29-04:01:36, 04:04:01-04:05, 04:07-04:09N, 04:12-04:15:03, 04:17-04:20, 04:24-04:28, 04:30-04:31, 04:34- 04:35, 04:38-04:41, 04:43- 04:53, 04:56-04:57, 04:59Q- 04:71, 04:73-04:76, 04:78- 04:79, 04:81-04:102, 04:104- 04:106
13					18							*04:01:16, 04:23, 04:54, 04:72
13								21				*04:01:23, 04:33
13					18			21				*04:01:28
13		15			18			21				*04:03, 04:06, 04:80
					18			21				*04:10
			16					21				*04:11
13		15			18			21				*04:16
13			16		18			21				*04:29
13					18			21	22			*04:32, 04:77
			16		18			21				*04:36, 04:55
13		15			18		20	21				*04:37
13	14				18			21		23		*04:42
13					18	19		21				*04:58
13		15			18			21				*04:103
13		15						21				*04:107
		15						21				*05:01:01:01-05:01:18, 05:03, 05:05-05:15, 05:18:01-05:19, 05:21, 05:24, 05:27-05:35, 05:37-05:41, 05:44-05:45, 05:47- 05:54, 05:56-05:57, 05:58:02- 05:61, 05:63-05:67, 05:69-05:72
		15										*05:04, 05:22:01-05:22:02
		15					20	21				*05:16
		15			18			21				*05:17, 05:25, 05:55, 05:68
								21				*05:20, 05:43
		15				19		21				*05:23, 05:62
		15						21				*05:26
		15		17				21				*05:36
13		15			18			21				*05:42
13		15						21				*05:46
		15						21				*05:58:01
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
<b>HLA-C allele<sup>4</sup></b>												
*06:02:01:01-06:02:01:02, 06:02:03-06:02:11, 06:02:13- 06:02:15, 06:02:17-06:02:19, 06:07, 06:10, 06:12-06:13, 06:15-06:16N, 06:18-06:30, 06:33-06:34, 06:36-06:39, 06:41- 06:51, 06:53-06:69								8			11	
*06:02:12, 06:11, 06:52								8				
*06:02:16, 06:04, 06:40								8			11	
*06:03			3					8			11	
*06:05								8			11	
*06:06								8			11	
*06:08		2						8			11	
*06:09								8			11	
*06:14, 06:35								8			11	
*06:17											11	
*06:31								8			11	
*06:32											11	
*07:01:01-07:02:07, 07:02:10- 07:02:28, 07:03-07:06, 07:08, 07:11-07:25, 07:27:01- 07:27:02, 07:29-07:30, 07:32N, 07:35-07:38, 07:42, 07:44- 07:48, 07:50-07:63, 07:65- 07:75, 07:77-07:91, 07:93- 07:95, 07:97-07:100, 07:102- 07:122, 07:124, 07:126-07:138, 07:140-07:147, 07:149-07:151, 07:153-07:155, 07:157-07:160, 07:162-07:172, 07:174-07:176, 07:178-07:183, 07:185-07:195, 07:197-07:209, 07:211-07:220									9			
*07:02:08, 07:02:29, 07:26, 07:33N, 07:39-07:40, 07:92, 07:139, 07:152N, 07:156									9			
*07:02:09						6			9			
*07:07, 07:09, 07:49, 07:76									9		11	
*07:10, 07:28, 07:41, 07:43, 07:184, 07:196									9			
*07:31									9			
*07:64									9			
*07:96			3						9			
*07:101, 07:148, 07:161		2							9	10		
<b>Well No.</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.	
												HLA-C allele <sup>4</sup>	
	14									23		*06:02:01:01-06:02:01:02, 06:02:03-06:02:11, 06:02:13- 06:02:15, 06:02:17-06:02:19, 06:07, 06:10, 06:12-06:13, 06:15-06:16N, 06:18-06:30, 06:33-06:34, 06:36-06:39, 06:41- 06:51, 06:53-06:69	
	14									23		*06:02:12, 06:11, 06:52	
										23		*06:02:16, 06:04, 06:40	
	14	15							22			*06:03	
					18		20			23		*06:05	
							20			23		*06:06	
	14									23		*06:08	
	14							21		23		*06:09	
								21		23		*06:14, 06:35	
	14						20			23		*06:17	
	14				18		20			23		*06:31	
	14									23		*06:32	
										23		Negative Control	
													*07:01:01-07:02:07, 07:02:10- 07:02:28, 07:03-07:06, 07:08, 07:11-07:25, 07:27:01- 07:27:02, 07:29-07:30, 07:32N, 07:35-07:38, 07:42, 07:44- 07:48, 07:50-07:63, 07:65- 07:75, 07:77-07:91, 07:93- 07:95, 07:97-07:100, 07:102- 07:122, 07:124, 07:126-07:138, 07:140-07:147, 07:149-07:151, 07:153-07:155, 07:157-07:160, 07:162-07:172, 07:174-07:176, 07:178-07:183, 07:185-07:195, 07:197-07:209, 07:211-07:220
													*07:02:08, 07:02:29, 07:26, 07:33N, 07:39-07:40, 07:92, 07:139, 07:152N, 07:156
13					18					23			*07:02:09
							20			23			*07:07, 07:09, 07:49, 07:76
								21		23			*07:10, 07:28, 07:41, 07:43, 07:184, 07:196
					18					23			*07:31
			16										*07:64
									22				*07:96
										23			*07:101, 07:148, 07:161
13	14	15	16	17	18	19	20	21	22	23	24	Well No.	



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
HLA-C allele <sup>4</sup>												
*07:123, 07:173									9			
*07:125						6			9			
*07:177									9			
*07:210									9		11	
*08:01:01-08:01:05, 08:03:01-08:03:02, 08:06, 08:08, 08:14, 08:16, 08:20, 08:22, 08:24, 08:26N, 08:28, 08:36N, 08:38, 08:40-08:42, 08:44, 08:46, 08:50, 08:56										10		
*08:02:01-08:02:07, 08:04, 08:13, 08:15:01-08:15:02, 08:17-08:19, 08:23, 08:27, 08:29-08:30, 08:32-08:35, 08:37, 08:39, 08:43, 08:45, 08:49, 08:51-08:55N										10		
*08:05, 08:25										10		
*08:07, 08:47										10		
*08:09, 08:11										10		
*08:10							7			10	11	
*08:12										10		
*08:21										10		
*08:31		2								10		
*08:48										10		
*12:02:01-12:02:07, 12:10:01-12:10:02, 12:17-12:18, 12:20, 12:22, 12:27, 12:30, 12:36, 12:40, 12:56, 12:64, 12:67-12:68												12
*12:03:01:01-12:03:01:02, 12:03:03, 12:03:05-12:03:07, 12:03:10-12:03:12, 12:03:14-12:03:15, 12:03:17-12:03:19, 12:06-12:07, 12:11-12:13, 12:19, 12:23, 12:25, 12:29, 12:32, 12:34-12:35, 12:37-12:39N, 12:42Q-12:43, 12:45-12:48, 12:50-12:53, 12:57, 12:61-12:63, 12:65-12:66												12
*12:03:02, 12:03:08, 12:03:16, 12:03:20, 12:26, 12:59												
*12:03:04												12
*12:03:09								8				12
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
				17						23		*07:123, 07:173
13	14									23		*07:125
					18							*07:177
							20					*07:210
					18			21				*08:01:01-08:01:05, 08:03:01-08:03:02, 08:06, 08:08, 08:14, 08:16, 08:20, 08:22, 08:24, 08:26N, 08:28, 08:36N, 08:38, 08:40-08:42, 08:44, 08:46, 08:50, 08:56
								21				*08:02:01-08:02:07, 08:04, 08:13, 08:15:01-08:15:02, 08:17-08:19, 08:23, 08:27, 08:29-08:30, 08:32-08:35, 08:37, 08:39, 08:43, 08:45, 08:49, 08:51-08:55N
13								21				*08:05, 08:25
						19		21				*08:07, 08:47
					18							*08:09, 08:11
		15			18			21				*08:10
							20	21				*08:12
13					18			21				*08:21
								21				*08:31
												*08:48
13												*12:02:01-12:02:07, 12:10:01-12:10:02, 12:17-12:18, 12:20, 12:22, 12:27, 12:30, 12:36, 12:40, 12:56, 12:64, 12:67-12:68
13	14											*12:03:01:01-12:03:01:02, 12:03:03, 12:03:05-12:03:07, 12:03:10-12:03:12, 12:03:14-12:03:15, 12:03:17-12:03:19, 12:06-12:07, 12:11-12:13, 12:19, 12:23, 12:25, 12:29, 12:32, 12:34-12:35, 12:37-12:39N, 12:42Q-12:43, 12:45-12:48, 12:50-12:53, 12:57, 12:61-12:63, 12:65-12:66
13	14											*12:03:02, 12:03:08, 12:03:16, 12:03:20, 12:26, 12:59
	14											*12:03:04
	14											*12:03:09
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
<b>HLA-C allele<sup>4</sup></b>												
*12:03:13												12
*12:04:01, 12:33											11	
*12:04:02, 12:60											11	12
*12:05											11	12
*12:08												12
*12:09											11	
*12:14:01												
*12:14:02												12
*12:15								8				12
*12:16												12
*12:21											11	12
*12:24												12
*12:28, 12:58												12
*12:31												12
*12:41											11	12
*12:44												12
*12:49												12
*12:54											11	12
*12:55												12
*14:02:01-14:02:07, 14:02:09-14:03, 14:05, 14:07N, 14:11, 14:13-14:14, 14:18-14:24, 14:26-14:27, 14:29-14:34												
*14:02:08												12
*14:04											11	
*14:06, 14:08-14:09, 14:28												
*14:10												
*14:12											11	
*14:15												
*14:16												
*14:17												
*14:25		2										
*15:02:01-15:02:07, 15:08, 15:10:02, 15:13, 15:15, 15:17-15:18, 15:26, 15:28, 15:31-15:35, 15:38-15:39, 15:41, 15:44-15:45, 15:47-15:53, 15:56			3					8			11	
*15:03, 15:16			3					8			11	
*15:04-15:06:03, 15:09, 15:19-15:20, 15:24, 15:27, 15:29-15:30, 15:40, 15:46, 15:54			3								11	
*15:07			3					8				
*15:10:01								8			11	
<b>Well No.</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
w	14											*12:03:13
	14	15										*12:04:01, 12:33
13	14	15										*12:04:02, 12:60
	14	15										*12:05
13				17								*12:08
		15					20					*12:09
13					18	19						*12:14:01
13					18	19						*12:14:02
13	14			17								*12:15
13										23		*12:16
		15										*12:21
13							20					*12:24
13	14				18							*12:28, 12:58
13	14							21				*12:31
13		15										*12:41
13								21				*12:44
												*12:49
13	14											*12:54
13	14		16									*12:55
			16				20					*14:02:01-14:02:07, 14:02:09-14:03, 14:05, 14:07N, 14:11, 14:13-14:14, 14:18-14:24, 14:26-14:27, 14:29-14:34
			16				20					*14:02:08
			16				20					*14:04
			16									*14:06, 14:08-14:09, 14:28
			16		18		20					*14:10
			16				20					*14:12
			16		18							*14:15
	14		16									*14:16
			16			19	20					*14:17
			16				20		22			*14:25
		15		17				21				*15:02:01-15:02:07, 15:08, 15:10:02, 15:13, 15:15, 15:17-15:18, 15:26, 15:28, 15:31-15:35, 15:38-15:39, 15:41, 15:44-15:45, 15:47-15:53, 15:56
13		15		17				21				*15:03, 15:16
		15		17				21				*15:04-15:06:03, 15:09, 15:19-15:20, 15:24, 15:27, 15:29-15:30, 15:40, 15:46, 15:54
				17				21				*15:07
		15		17				21				*15:10:01
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
HLA-C allele <sup>4</sup>												
*15:11			3			6		8			11	
*15:12					5			8			11	
*15:21			3					8				
*15:22, 15:55			3								11	
*15:23											11	
*15:25			3									
*15:36						6					11	
*15:37			3					8			11	
*15:42		2	3					8			11	
*15:43			3					8				
*16:01:01-16:01:07, 16:06-16:08, 16:10-16:11, 16:13-16:15:01, 16:16Q-16:17, 16:21-16:24, 16:26-16:28, 16:30N-16:32, 16:36, 16:38-16:39, 16:41, 16:44												
*16:02:01-16:02:09, 16:09, 16:12, 16:19, 16:25											11	
*16:04, 16:33, 16:42												
*16:15:02												12
*16:18, 16:37												
*16:20												
*16:29		2										
*16:34			3			6						
*16:35												
*16:40							7					
*16:43												
*17:01:01:01-17:01:03, 17:01:05-17:06, 17:08-17:11		2									11	
*17:01:04		2									11	
*17:07											11	
*18:01-18:02, 18:04-18:05											11	
*18:03		2									11	
A*24:106, A*24:174, B*46:25												
B*14:03												
B*67:02												
HLA-C allele <sup>4</sup>												
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

13	14	15	16	17	18	19	20	21	22	23	24	Well No.
												HLA-C allele <sup>4</sup>
		15		17				21				*15:11
		15		17	18			21				*15:12
		15		17				21				*15:21
		15		17								*15:22, 15:55
				17				21				*15:23
13					18	19		21				*15:25
				17				21				*15:36
		15		17								*15:37
		15		17				21				*15:42
				17				21	22			*15:43
13					18					23		*16:01:01-16:01:07, 16:06-16:08, 16:10-16:11, 16:13-16:15:01, 16:16Q-16:17, 16:21-16:24, 16:26-16:28, 16:30N-16:32, 16:36, 16:38-16:39, 16:41, 16:44
13		15			18					23		*16:02:01-16:02:09, 16:09, 16:12, 16:19, 16:25
	14				18		20					*16:04, 16:33, 16:42
13					18					23		*16:15:02
13		15			18					23		*16:18, 16:37
13				17	18					23		*16:20
	14				18		20					*16:29
13					18					23		*16:34
					18							*16:35
			16									*16:40
13										23		*16:43
		15				19		21				*17:01:01-17:01:03, 17:01:05-17:06, 17:08-17:11
13		15				19		21				*17:01:04
		15				19		21				*17:07
							20	21		23		*18:01-18:02, 18:04-18:05
							20	21	22	23		*18:03
										23		A*24:106, A*24:174, B*46:25
							20					B*14:03
13												B*67:02
												HLA-C allele <sup>4</sup>
13	14	15	16	17	18	19	20	21	22	23	24	Well No.

Negative Control

101.603.24/12 – including **Taq pol.**, IFU-01 Rev. No. 03  
101.603.24u/12u – without **Taq pol.**, IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

#### Lot-specific information

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C low resolution SSP typing.

In addition, wells number 2, 3, 5, 6, 8 to 10, 12 to 15, 17, 19, 20 and 24 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to allow kit identification.

<sup>2</sup>The nucleotide position, in the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> or 4<sup>th</sup> exon or the 1<sup>st</sup> or 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position, in the 2<sup>nd</sup>, 3<sup>rd</sup> or 4<sup>th</sup> exon or the 3<sup>rd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>4</sup>The sequence of the Cw\*0101 allele has been shown to be identical to C\*01:02:01.

The sequence of the Cw\*0201 allele has been shown to be identical to C\*02:02:02.

The sequence of the Cw\*020204 allele has been shown to be identical to C\*02:10.

The sequence of the Cw\*021603 allele has been shown to be identical to C\*02:16:02.

The sequence of the Cw\*0301 allele has been shown to be identical to C\*03:04:01:01.

The sequence of the Cw\*0402 allele has been shown to be identical to C\*04:01:01:01.

The sequence of the Cw\*0421 allele has been shown to be identical to C\*04:15:02.

The sequence of the Cw\*0422 allele has been shown to be identical to C\*04:21.

The sequence of the Cw\*0502 allele has been shown to be identical to C\*05:09.

The sequence of the Cw\*0601 allele has been shown to be identical to C\*06:02:01:01.

The sequence of the Cw\*060202 allele has been renamed C\*06:17.

The sequence of the Cw\*0734 allele has been renamed C\*07:27:02.

The sequence of the Cw\*1101 allele has been shown to be in error.

The sequence of the Cw\*1201 allele has been shown to be identical to C\*12:02:02.

The sequence of the Cw\*1301 allele has been shown to be in error.

The sequence of the Cw\*1401 allele has been shown to be identical to C\*14:02:01.

The sequence of the Cw\*1501 allele has been shown to be identical to C\*15:02:01.

The sequence of the Cw\*1514 allele has been renamed C\*15:10:02.

The sequence of the Cw\*1603 allele has been shown to be identical to C\*14:03.

The sequence of the Cw\*16042 allele has been shown to be identical to C\*16:04:01.

The sequence of the Cw\*1605 allele has been shown to be identical to C\*16:04:01.

<sup>5</sup>The C\*01:05, 01:22 and 01:35-01:36 and the B\*54:18 alleles give rise to identical amplification patterns with the HLA-C low resolution primer set. These alleles are separated by the HLA-B low primer set.

<sup>6</sup>Primer mix 24 contains a negative control, which will amplify more than 95% of HLA amplicons as well as amplicons generated by control primer pairs. PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the control primer pair is 430 base pairs.

'w', might be weakly amplified.



101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

				<b>CELL LINE VALIDATION SHEET</b>																
				<b>HLA-C low resolution screening SSP primer set</b>																
				<b>Well</b>																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201188801	201188802	201188803	201188804	201188805	201200306	201200307	201200308	201188809	201188810	201188811	201200312	201202213	201188814	201188815	201200316
<b>IHWC cell line</b>		<b>C*</b>																		
1	9001	SA	*07:02	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
2	9280	LK707	*07:01	*15:05	-	-	+	-	-	-	-	-	+	-	+	-	-	-	+	-
3	9011	E4181324	*12:02		-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
4	9275	GU373	*03:04	*04:01	-	-	+	+	-	+	-	-	-	-	+	-	+	-	-	-
5	9009	KAS011	*06:02		-	-	-	-	-	-	-	-	+	-	-	+	-	-	+	-
6	9353	SM	*03:04	*07:02	-	-	+	+	-	-	-	-	+	-	-	-	-	-	-	-
7	9020	QBL	*05:01		-	-	-	-	-	-	-	+	-	-	+	-	-	-	+	-
8	9025	DEU	*04:01		-	-	-	-	-	-	+	-	-	-	-	+	-	+	-	-
9	9026	YAR	*12:03		-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
10	9107	LKT3	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-
12	9052	DBB	*06:02		-	-	-	-	-	-	-	-	+	-	-	+	-	-	+	-
13	9004	JESTHOM	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*01:02	*03:04	+	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*03:04		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*02:02		-	+	+	-	-	+	-	-	-	-	-	+	-	-	-	+
17	9282	CTM3953540	*03:03	*07:01	-	-	-	+	+	-	-	-	+	-	-	-	-	-	-	-
18	9257	32367	*01:02	*07:05	+	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
19	9038	BM16	*07:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
20	9059	SLE005	*03:04		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*03:03		-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
22	9056	KOSE	*12:03		-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
23	9124	IHL	*01:02	*15:02	+	-	+	-	-	-	-	+	-	-	+	-	-	-	+	-
24	9035	JBUSH	*12:03		-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
25	9049	IBW9	*08:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
26	9285	WT49	*07:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
27	9191	CH1007	*07:04	*15:05	-	-	+	-	-	-	-	-	+	-	+	-	-	-	+	-
28	9320	BEL5GB	*05:01	*16:01	-	-	-	-	-	-	-	+	-	-	+	-	+	-	+	-
29	9050	MOU	*16:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
30	9021	RSH	*17:01		-	+	-	-	-	-	-	-	-	-	+	-	-	-	+	-
31	9019	DUCAF	*05:01		-	-	-	-	-	-	+	-	-	-	+	-	-	-	+	-
32	9297	HAG	*17:01	*17:03	-	+	-	-	-	-	-	-	-	-	+	-	-	-	+	-
33	9098	MT14B	*03:04		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*12:03		-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
35	9302	SSTO	*05:01		-	-	-	-	-	-	-	+	-	-	+	-	-	-	+	-
36	9024	KT17	*03:03	*04:01	-	-	-	+	+	+	-	-	-	-	+	-	+	-	-	-
37	9065	HHKB	*07:02		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
38	9099	LZL	*03:03		-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
39	9315	CML	*02:02	*07:01	-	+	+	-	-	+	-	-	+	-	+	-	-	-	+	-
40	9134	WHONP199	*01:02	*06:02	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	-
41	9055	H0301	*08:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
42	9066	TAB089	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*01:02	*08:01	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
44	9057	TEM	*12:03		-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
45	9239	SHJO	*06:02	*17:01	-	+	-	-	-	-	-	+	-	-	+	-	-	+	+	-
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
47	9045	TUBO	*07:04	*15:02	-	-	+	-	-	-	-	+	-	-	+	-	-	-	+	-
48	9303	TER-ND	*04:01	*16:01	-	-	-	-	-	+	-	-	-	-	+	-	+	-	-	-

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

CELL LINE VALIDATION SHEET											
HLA-C low resolution screening SSP primer set											
				Well							
				17	18	19	20	21	22	23	
				Prod. No.:	201200317	201188818	201188819	201188820	201188821	201188822	201188823
IHWC cell line		C*									
1	9001 SA	*07:02		-	-	-	-	-	-	+	
2	9280 LK707	*07:01	*15:05	+	-	-	-	+	-	+	
3	9011 E4181324	*12:02		-	-	-	-	-	-	-	
4	9275 GU373	*03:04	*04:01	-	+	-	-	+	+	-	
5	9009 KAS011	*06:02		-	-	-	-	-	-	+	
6	9353 SM	*03:04	*07:02	-	-	-	-	+	+	+	
7	9020 QBL	*05:01		-	-	-	-	+	-	-	
8	9025 DEU	*04:01		-	+	-	-	+	-	-	
9	9026 YAR	*12:03		-	-	-	-	-	-	-	
10	9107 LKT3	*01:02		-	-	-	+	-	-	-	
11	9051 PITOUT	*16:01		-	+	-	-	-	-	-	
12	9052 DBB	*06:02		-	-	-	-	-	-	+	
13	9004 JESTHOM	*01:02		-	-	-	+	-	-	-	
14	9071 OLGA	*01:02	*03:04	-	-	-	+	+	+	-	
15	9075 DKB	*03:04		-	-	-	-	+	+	-	
16	9037 SWEIG007	*02:02		-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:03	*07:01	-	-	-	-	+	+	+	
18	9257 32367	*01:02	*07:05	-	-	-	+	-	-	+	
19	9038 BM16	*07:01		-	-	-	-	-	-	+	
20	9059 SLE005	*03:04		-	-	-	-	+	+	-	
21	9064 AMALA	*03:03		-	-	-	-	+	+	-	
22	9056 KOSE	*12:03		-	-	-	-	-	-	-	
23	9124 IHL	*01:02	*15:02	+	-	-	+	+	-	-	
24	9035 JBUSH	*12:03		-	-	-	-	-	-	-	
25	9049 IBW9	*08:02		-	-	-	-	+	-	-	
26	9285 WT49	*07:01		-	-	-	-	-	-	+	
27	9191 CH1007	*07:04	*15:05	+	-	-	-	+	-	+	
28	9320 BEL5GB	*05:01	*16:01	-	+	-	-	+	-	-	
29	9050 MOU	*16:01		-	+	-	-	-	-	-	
30	9021 RSH	*17:01		-	-	+	-	+	-	-	
31	9019 DUCAF	*05:01		-	-	-	-	+	-	-	
32	9297 HAG	*17:01	*17:03	-	-	+	-	+	-	-	
33	9098 MT14B	*03:04		-	-	-	-	+	+	-	
34	9104 DHIF	*12:03		-	-	-	-	-	-	-	
35	9302 SSTO	*05:01		-	-	-	-	+	-	-	
36	9024 KT17	*03:03	*04:01	-	+	-	-	+	+	-	
37	9065 HHKB	*07:02		-	-	-	-	-	-	+	
38	9099 LZL	*03:03		-	-	-	-	+	+	-	
39	9315 CML	*02:02	*07:01	-	-	-	-	-	-	+	
40	9134 WHONP199	*01:02	*06:02	-	-	-	+	-	-	+	
41	9055 H0301	*08:02		-	-	-	-	+	-	-	
42	9066 TAB089	*01:02		-	-	-	+	-	-	-	
43	9076 T7526	*01:02	*08:01	-	+	-	+	+	-	-	
44	9057 TEM	*12:03		-	-	-	-	-	-	-	
45	9239 SHJO	*06:02	*17:01	-	-	+	-	+	-	+	
46	9013 SCHU	*07:02		-	-	-	-	-	-	+	
47	9045 TUBO	*07:04	*15:02	+	-	-	-	+	-	+	
48	9303 TER-ND	*04:01	*16:01	-	+	-	-	+	-	-	

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
 101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

## CERTIFICATE OF ANALYSIS

### Olerup SSP® HLA-C low resolution screening SSP

**Product number:** 101.603-24/12 – including *Taq* pol.  
 101.603-24u/12u – without *Taq* pol.  
**Lot number:** 81N  
**Expiry date:** 2014-October-01  
**Number of tests:** 24 tests – Product No. 101.603-24/24u  
 12 tests – Product No. 101.603-12/12u  
**Number of wells per test:** 23 + 1

#### Well specifications:

Well No.	Production No.	Well No.	Production No.	Well No.	Production No.
1	2011-888-01	9	2011-888-09	17	2012-003-17
2	2011-888-02	10	2011-888-10	18	2011-888-18
3	2011-888-03	11	2011-888-11	19	2011-888-19
4	2011-888-04	12	2012-003-12	20	2011-888-20
5	2011-888-05	13	2012-022-13	21	2011-888-21
6	2012-003-06	14	2011-888-14	22	2011-888-22
7	2012-003-07	15	2011-888-15	23	2011-888-23
8	2012-003-08	16	2012-003-16		

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

Additional 5'-primers in primer solution 2, 6, 7, 13 to 16, 22 and 23 were tested by separately adding one 3'-primer. Additional 3'-primers in primer solutions 2, 7, 10, 14 to 16, 18, 19 and 22 were tested by separately adding one 5'-primer. In primer solutions 3, 11, 12, 14 and 18, one or two 3'-primers were not possible to test, and in primer solution 23 one 5'-primer was not possible to test.

The negative control primer pairs, **Production No. 2012-002-01**, can detect contamination with PCR products diluted  $10^{-7}$ .

**Results:** No false positive or false negative amplifications were obtained.

**Date of approval:** 2012-April-26

**Approved by:**

#### Production Quality Control

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

## Declaration of Conformity

**Product name:** *Olerup* SSP® HLA-C low resolution screening  
**Product number:** 101.603-24/24u, -12/12u  
**Lot number:** 81N

**Intended use:** HLA-C low resolution histocompatibility testing

**Manufacturer:** *Olerup* SSP AB  
Franzengatan 5  
SE-112 51 Stockholm, Sweden  
**Phone:** +46-8-717 88 27  
**Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2004, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex III, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Stockholm, Sweden  
2012-May-10

Ann-Cathrin Jareman  
Head of QA and Regulatory Affairs

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

101.603.24/12 – including *Taq* pol., IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq* pol., IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

101.603.24/12 – including *Taq pol.*, IFU-01 Rev. No. 03  
101.603.24u/12u – without *Taq pol.*, IFU-02 Rev. No. 03

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **81N**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [info-ssp@olerup.com](mailto:info-ssp@olerup.com)

**Web page:** <http://www.olerup-ssp.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [support-at@olerup.com](mailto:support-at@olerup.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [info.us@olerup.com](mailto:info.us@olerup.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.